Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Incheon St.Mary's Hospital
H. Lee Moffitt Cancer Center and Research Institute
University of Pittsburgh
HistoSonics, Inc.
Coherus Oncology, Inc.
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
Hospices Civils de Lyon
Washington University School of Medicine
Pfizer
Bristol-Myers Squibb
Genentech, Inc.
Memorial Sloan Kettering Cancer Center
University of Iowa
Birmingham Women's and Children's NHS Foundation Trust
Five Eleven Pharma, Inc.
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey
Bristol-Myers Squibb
Astellas Pharma Inc
Kidney Cancer Research Bureau
M.D. Anderson Cancer Center
Taiho Oncology, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University Hospital, Angers
University Hospital, Bordeaux
Cedars-Sinai Medical Center
Celldex Therapeutics
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Corvus Pharmaceuticals, Inc.
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ludwig Institute for Cancer Research
Novartis
Barbara Ann Karmanos Cancer Institute
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Northwestern University
Washington University School of Medicine
Janssen Research & Development, LLC
National Institutes of Health Clinical Center (CC)
Calithera Biosciences, Inc
Quadriga Biosciences, Inc.